-
Study examines impact of voluntary, mandatory mail on medication adherence
NEW YORK — Mandatory mail seems to cause some patients to prematurely discontinue therapy, especially among those patients without previous mail-service pharmacy experience. At least, that’s what a recent study on mandatory mail suggested.
The CVS Caremark-funded study, “Adherence to Medication Under Mandatory and Voluntary Mail Benefit Designs,” recently was published in the American Journal of Managed Care.
-
GSK, XenoPort file sNDA for Horizant
LONDON — Drug makers GlaxoSmithKline and XenoPort are seeking expanded approval for their restless legs syndrome treatment.
The drug makers this week announced the submission of a supplemental new drug application to the Food and Drug Administration, requesting approval for Horizant (gabapentin enacarbil) extended-release tablets as a treatment for postherpetic neuralgia, a nerve pain that commonly is seen in patients with shingles. GSK submitted the sNDA on behalf of the two companies.